SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2016 / Cilt: 64 - Sayı: 3

New bronchodilators and combinations in COPD treatment

KOAH tedavisinde yeni bronkodilatörler ve kombinasyonları

Muzaffer SARIAYDIN
Sibel GÜNAY
Nilgün YILMAZ DEMİRCİ
Pages
240–245
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, with the guidence of the current literature, the effects of new beta-2 agonists and anticholinergic bronchodilators will be discussed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bronchodilator drugs are widely used therapeutic agents for treatment of asthma and chronic obstructive pulmonary disease (COPD).
📊
Key Findings & Data:In order to mantain bronchodilation, both sympathetic system (particularly beta-2 receptors) activation and parasympathetic system inhibition (antimuscarinic effect) mechanisms are utilized.
💡
Conclusion & Impact:In this review, with the guidence of the current literature, the effects of new beta-2 agonists and anticholinergic bronchodilators will be discussed
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Bronchodilator drugs are widely used therapeutic agents for treatment of asthma and chronic obstructive pulmonary disease (COPD). In order to mantain bronchodilation, both sympathetic system (particularly beta-2 receptors) activation and parasympathetic system inhibition (antimuscarinic effect) mechanisms are utilized. Over 20 years, there were no significant changes in bronchodilator therapy in obstructive pulmonary diseases. In recent years, however, after the development of new ultra long acting bronchodilator drugs, a single dose inhaler treatments per day in the treatment of stable COPD became a current issue. In this review, with the guidence of the current literature, the effects of new beta-2 agonists and anticholinergic bronchodilators will be discussed

Özet

Bronkodilatör ilaçlar, kronik obstrüktif akciğer hastalığı (KOAH) ve astım tedavisinde yaygın olarak kullanılan tedavilerdir. Bronkodilatasyon için hem sempatik sistem (özellikle beta-2 reseptörler) aktivasyonu hem de parasempatik sistemin inhibisyonu (antimuskarinik etki) mekanizmalarından faydalanılır. KOAH'ta kullanılan bronkodilatör tedavilerde, 20 yılı aşkın süredir belirgin bir değişiklik olmamıştır. Ancak son yıllarda yeni, ultra uzun etkili bronkodilatör ilaçların geliştirilmesi ile stabil KOAH tedavisinde günde tek doz inhaler tedavi uygulamaları gündeme geldi. Bu derlemede literatürde bildirilen çalışmaların sonuçları ışığında yeni, ultra uzun etkili beta-2 agonist ve antikolinerjik bronkodilatör tedavilerin etkinlikleri tartışılacaktır.

🔖

Cite This Article

SARIAYDIN, M., GÜNAY, S., DEMİRCİ, N. Y. (2022). New bronchodilators and combinations in COPD treatment. Tüberküloz ve Toraks, Cilt: 64 - Sayı: 3, 240–245. https://ajindex.com/articles/618526

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. GOLD 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf.
  2. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. Calverley PMA. Symptomatic bronchodilator treatment. In: Calverley PMA, Pride NB (eds). Chronic obstructive pulmonary disease. London: Chapman and Hall, 1995:419-45.
  3. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
  4. O'Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA,Kalberg CJ, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006;130:647-56. Patel HJ. An update on pharmacological management of chronic obstructive pulmonary disease. Curr Opin Pulm Med 2016;22:119-24.
  5. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2- agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
  6. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C; INSIST study group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011;105:719-26.
  7. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Oncedaily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9.
  8. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011;38:797-803.
  9. Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, et al. INHANCE Study Investigators. Oncedaily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
  10. Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, et al. INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, bl